(dtpa-phe(1))-octreotide has been researched along with Adenoma--Oxyphilic* in 2 studies
2 other study(ies) available for (dtpa-phe(1))-octreotide and Adenoma--Oxyphilic
| Article | Year |
|---|---|
Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid.
Ten consecutive patients with Hürthle cell lesions of the thyroid (nodule/adenoma/carcinoma) were studied by (111)In-DTPA-D-Phe1-octreotide scintigraphy. Octreotide scintigraphy localized the primary Hürthle cell tumour in eight patients as distinct areas of increased uptake of radionuclide. Two patients with Hürthle cell carcinoma, previously thyroidectomized, had their metastases visualized by octreotide scintigraphy. Northern analyses showed expression of multiple somatostain receptor subtypes. Visualization of the Hürthle cell tumour may be due to a higher expression of somatostatin receptors in the lesions than in surrounding normal thyroid tissue. The tissue/blood (111)In concentration ratios for tumour samples from five patients showed clearly higher values than observed for normal connective tissue, muscle or lymph nodes. A relatively high uptake of (111)In was also observed in goiter tissue, which may lead to misinterpretations. The main indication for octreotide scintigraphy in patients with Hürthle cell carcinoma is suspicion of metastatic disease. Topics: Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Blotting, Northern; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasm Proteins; Octreotide; Pentetic Acid; Radionuclide Imaging; Receptors, Somatostatin; RNA, Messenger; Thyroid Neoplasms | 1999 |
Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
Somatostatin receptor expression, which was not a previously described marker for Hürthle cell cancer of the thyroid, was demonstrated by in vivo imaging with (111)In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hürthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds. Topics: Adenoma, Oxyphilic; Aged; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms | 1998 |